Literature DB >> 27313711

Patients treated with radical prostatectomy with positive digital rectal examination findings in the intermediate-risk group are prone to PSA recurrence.

Nobuki Furubayashi1, Takahito Negishi1, Shintaro Ura1, Jun Mutaguchi1, Kenichi Taguchi2, Mototsugu Shimokawa3, Motonobu Nakamura1.   

Abstract

The present study aimed to evaluate the possibility of performing radical prostatectomy (RP) alone to achieve a radical cure for prostate cancer in the intermediate-risk group. Samples were collected from 638 Japanese patients who underwent antegrade RP between August 1998 and May 2013; subsequently, 157 patients were excluded. According to the D'Amico criteria, the low-, intermediate- and high-risk groups comprised 107, 222 and 152 patients, respectively. The 5-year prostate-specific antigen (PSA) failure-free survival rates in the low-, intermediate-, and high-risk groups were 96.5, 88.9 and 72.6%, respectively (P<0.001; degrees of freedom=2). In the intermediate-risk group, the difference in PSA failure-free survival between the 0<PSA≤10 and 10<PSA≤20 ng/ml, and the biopsy Gleason score 6 and 7 groups were not statistically significant, according to the log-rank test (P=0.2266 and P=0.1329, respectively). However, the difference in PSA failure-free survival between the clinical tumor stage (cT)1c and cT2a/b groups was statistically significant based on the log-rank test (P<0.0001). The results of the multivariate analysis revealed that, of the preoperative characteristics, only the cT was a significant predictor in patients with and without PSA failure (P<0.001). Therefore, patients classified into the intermediate-risk group with cT2a/b stage, according to positive digital rectal examination findings, and are not considered to be likely to achieve a complete cure with RP surgery alone. In summary, for patients meeting these criteria in the intermediate-risk group, RP surgery alone is likely to be insufficient, and other additional treatments may be considered subsequent to RP.

Entities:  

Keywords:  digital rectal examination; intermediate-risk; prostate cancer; prostate-specific antigen recurrence; radical prostatectomy

Year:  2016        PMID: 27313711      PMCID: PMC4888263          DOI: 10.3892/ol.2016.4485

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  30 in total

1.  Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging.

Authors:  D F Gleason; G T Mellinger
Journal:  J Urol       Date:  1974-01       Impact factor: 7.450

2.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.

Authors:  W J Catalona; D S Smith; D K Ornstein
Journal:  JAMA       Date:  1997-05-14       Impact factor: 56.272

3.  Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy.

Authors:  T Y Chan; A W Partin; P C Walsh; J I Epstein
Journal:  Urology       Date:  2000-11-01       Impact factor: 2.649

4.  Time trends and local variation in primary treatment of localized prostate cancer.

Authors:  Matthew R Cooperberg; Jeanette M Broering; Peter R Carroll
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

5.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

6.  Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era.

Authors:  Hendrik Isbarn; Manuela Wanner; Georg Salomon; Thomas Steuber; Thorsten Schlomm; Jens Köllermann; Guido Sauter; Alexander Haese; Hans Heinzer; Hartwig Huland; Markus Graefen
Journal:  BJU Int       Date:  2009-12-11       Impact factor: 5.588

7.  Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios.

Authors:  J E Oesterling; S J Jacobsen; G G Klee; K Pettersson; T Piironen; P A Abrahamsson; U H Stenman; B Dowell; T Lövgren; H Lilja
Journal:  J Urol       Date:  1995-09       Impact factor: 7.450

Review 8.  MRI of the prostate.

Authors:  M D Rifkin
Journal:  Crit Rev Diagn Imaging       Date:  1990

Review 9.  Radical prostatectomy for low risk carcinoma of the prostate.

Authors:  Joseph A Smith
Journal:  World J Urol       Date:  2008-07-02       Impact factor: 4.226

Review 10.  The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy.

Authors:  J S Wolf; M Cher; M Dall'era; J C Presti; H Hricak; P R Carroll
Journal:  J Urol       Date:  1995-03       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.